New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
07:38 EDTMDVNMedivation removed from Key Call List at UBS
UBS removed Medivation from the Key Call List given relative outperformance. Shares remain Buy rated with a $93 price target.
News For MDVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
09:18 EDTMDVNMedivation price target raised to $163 from $126 at Maxim
Subscribe for More Information
08:22 EDTMDVNMedivation price target raised to $163 from $126 at Maxim
Subscribe for More Information
07:24 EDTMDVNStifel to hold a bus tour
BioTrek: 2015 West Coast Healthcare Therapeutics Bus Tour travels throughout San Francisco on March 30-April 1.
March 27, 2015
06:55 EDTMDVNMedivation price target raised to $150 from $133 at Barclays
Subscribe for More Information
March 25, 2015
09:06 EDTMDVNMedivation price target raised to $144 from $123 at William Blair
Subscribe for More Information
07:53 EDTMDVNMedivation reported strong, positive results, says JMP Securities
JMP Securities says that the results of a study comparing Medivation's Xtandi to bicalutamide, the market leading prostate cancer medication, were strong and positive for Medivation. The firm continues to expect Xtandi to prove to be superior to bicalutamide. It expects Xtandi to generate $8B in worldwide revenue and raised its price target on Medivation to $143 from $126 while keeping an Outperform rating on the shares.
07:39 EDTMDVNMedivation price target raised to $142 from $125 at Brean Capital
Brean Capital raised its price target on Medivation to $142 from $125 following the presentation of additional Phase 2 TERRAIN trial data in metastatic castration-resistant prostate cancer and final OS data from the Phase 3 PREVAIL trial in chemo-naive mCRPC. The firm remains optimistic by consistent and positive data and reiterated its Buy rating on Medivation shares.
07:02 EDTMDVNMedivation price target raised to $148 from $130 at JPMorgan
Subscribe for More Information
March 24, 2015
07:07 EDTMDVNAstellas Pharma and Medivation report data from Phase 2 Terrain trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use